📊 TIL Key Takeaways
Is Instil Bio, Inc. (TIL) a Good Investment?
Instil Bio is a pre-revenue biotech company facing critical liquidity crisis with only ~2.2 months of cash runway ($6.6M cash against -$36.6M annual burn). Zero revenue combined with -$78.6M operating losses indicates failed or stalled product development with no near-term commercialization path. Without immediate capital raise or dramatic expense reduction, the company faces existential risk.
Why Buy Instil Bio, Inc. Stock? TIL Key Strengths
- Zero debt burden (Debt/Equity 0.00x) eliminates bankruptcy risk from creditors
- Asset base of $203.5M provides some tangible value, though immediate liquidity is critical
- Operating loss improved 3.7% YoY, suggesting cost controls or restructuring efforts
TIL Stock Risks: Instil Bio, Inc. Investment Risks
- Critical cash runway of approximately 2.2 months at current burn rate poses imminent solvency risk
- Zero revenue with no disclosed path to commercialization; suggests failed candidates or extremely early stage development
- Severe value destruction evidenced by ROE of -62.7% and ROA of -35.1% signals unsustainable business model
- Massive operating losses (-$78.6M) on zero revenue indicate fundamental business challenges beyond typical biotech risk
- Dilutive capital raise likely imminent, threatening shareholder equity
Key Metrics to Watch
- Cash balance and monthly burn rate (critical for survival timeline)
- Capital raise announcements and terms (equity dilution risk)
- Clinical/regulatory progress on product candidates and potential revenue catalysts
- Operating expense trends and path to sustainability
Instil Bio, Inc. (TIL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 39.53x current ratio provides a solid financial cushion.
TIL Profit Margin, ROE & Profitability Analysis
TIL vs Healthcare Sector: How Instil Bio, Inc. Compares
How Instil Bio, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Instil Bio, Inc. Stock Overvalued? TIL Valuation Analysis 2026
Based on fundamental analysis, Instil Bio, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Instil Bio, Inc. Balance Sheet: TIL Debt, Cash & Liquidity
TIL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Instil Bio, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-11.39 indicates the company is currently unprofitable.
TIL Revenue Growth, EPS Growth & YoY Performance
TIL Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2021 | N/A | -$4.1M | $-0.33 |
| Q2 2021 | N/A | -$4.1M | $-0.27 |
| Q1 2021 | N/A | -$4.1M | $-0.31 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Instil Bio, Inc. Dividends, Buybacks & Capital Allocation
TIL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Instil Bio, Inc. (CIK: 0001789769)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TIL
What is the AI rating for TIL?
Instil Bio, Inc. (TIL) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TIL's key strengths?
Claude: Zero debt burden (Debt/Equity 0.00x) eliminates bankruptcy risk from creditors. Asset base of $203.5M provides some tangible value, though immediate liquidity is critical.
What are the risks of investing in TIL?
Claude: Critical cash runway of approximately 2.2 months at current burn rate poses imminent solvency risk. Zero revenue with no disclosed path to commercialization; suggests failed candidates or extremely early stage development.
What is TIL's revenue and growth?
Instil Bio, Inc. reported revenue of $0.0.
Does TIL pay dividends?
Instil Bio, Inc. does not currently pay dividends.
Where can I find TIL SEC filings?
Official SEC filings for Instil Bio, Inc. (CIK: 0001789769) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TIL's EPS?
Instil Bio, Inc. has a diluted EPS of $-10.70.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TIL a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Instil Bio, Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TIL stock overvalued or undervalued?
Valuation metrics for TIL: ROE of -62.7% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy TIL stock in 2026?
Our dual AI analysis gives Instil Bio, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TIL's free cash flow?
Instil Bio, Inc.'s operating cash flow is $-36.6M, with capital expenditures of $0.0.
How does TIL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -62.7% (avg: 15%), current ratio 39.53 (avg: 2).